Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression

• Published in: Human genomics Vol. 17; no. 1; p. 33
• Main Authors: Yang, Zhihao, Zheng, Yinfei, Wu, Haoyuan, Xie, Han, Zhao, Jiajia, Chen, Zhigang, Li, Lianxin, Yue, Xiaoyu, Zhao, Bing, Bian, Erbao
• Format: Journal Article
• Language: English
• Published: England BioMed Central 31-03-2023; BMC
• Subjects: Animals; Brain cancer; Brain tumors; Cancer therapies; Cell Cycle Proteins; Cell proliferation; Chemotherapy; Disease Models, Animal; Enhancers; Epigenetics; Fibroblasts; Gene expression; Genomes; Genomics; Glioma; Glioma - genetics; Glioma cells; Humans; Immunoregulation; Immunotherapy; Leukocyte migration; lncRNA; Lymphocytes T; Macrophages; Medical prognosis; Metastasis; Mice; Microenvironments; Non-coding RNA; Nuclear Proteins; Pathogenesis; Patients; Prognosis; Prognostic signature; Risk groups; RNA, Long Noncoding - genetics; Super-enhancer; Therapeutic applications; Therapeutic targets; Transcription Factors; Tumor Microenvironment - genetics; Tumors; Xenografts; United States > US; China; Prognostic signature; Super-enhancer; lncRNA; Glioma; Immunotherapy
• ISSN: 1479-7364; 1473-9542; 1479-7364
• DOI: 10.1186/s40246-023-00480-w

Super-enhancers (SEs), driving high-level expression of genes with tumor-promoting functions, have been investigated recently. However, the roles of super-enhancer-associated lncRNAs (SE-lncRNAs) in tumors remain undetermined, especially in gliomas. We here established a SE-lncRNAs expression-based prognostic signature to choose the effective treatment of glioma and identify a novel therapeutic target.
Combined analysis of RNA sequencing (RNA-seq) data and ChIP sequencing (ChIP-seq) data of glioma patient-derived glioma stem cells (GSCs) screened SE-lncRNAs. Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) datasets served to construct and validate SE-lncRNA prognostic signature. The immune profiles and potential immuno- and chemotherapies response prediction value of the signature were also explored. Moreover, we verified the epigenetic activation mechanism of LINC00945 via the ChIP assay, and its effect on glioma was determined by performing the functional assay and a mouse xenograft model.
6 SE-lncRNAs were obtained and identified three subgroups of glioma patients with different prognostic and clinical features. A risk signature was further constructed and demonstrated to be an independent prognostic factor. The high-risk group exhibited an immunosuppressive microenvironment and was higher enrichment of M2 macrophage, regulatory T cells (Tregs), and Cancer-associated fibroblasts (CAFs). Patients in the high-risk group were better candidates for immunotherapy and chemotherapeutics. The SE of LINC00945 was further verified via ChIP assay. Mechanistically, BRD4 may mediate epigenetic activation of LINC00945. Additionally, overexpression of LINC00945 promoted glioma cell proliferation, EMT, migration, and invasion in vitro and xenograft tumor formation in vivo.
Our study constructed the first prognostic SE-lncRNA signature with the ability to optimize the choice of patients receiving immuno- and chemotherapies and provided a potential therapeutic target for glioma.